Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$149 Mln
P/E Ratio
--
P/B Ratio
1.09
Industry P/E
--
Debt to Equity
0.05
ROE
-0.37 %
ROCE
-36.13 %
Div. Yield
0 %
Book Value
1.11
EPS
-0.5
CFO
CHF-249.32 Mln
EBITDA
CHF-249.04 Mln
Net Profit
CHF-268.09 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
AC Immune SA - ADR
| -41.85 | -25.24 | -42.07 | -35.12 | -25.19 | -26.92 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
AC Immune SA - ADR
| 145.10 | -58.79 | -4.26 | -39.32 | -9.84 | -26.05 | -1.39 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The... company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Address: Building B, Lausanne, Switzerland, 1015 Read more
Co-Founder, CEO & Director
Dr. Andrea Pfeifer Ph.D.
Co-Founder, CEO & Director
Dr. Andrea Pfeifer Ph.D.
Headquarters
Lausanne
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of AC Immune SA - ADR stood at $ 231 Mln as on 31-Dec-24
The share price of AC Immune SA - ADR is $1.57 (NASDAQ) as of 23-Apr-2025 13:39 EDT. AC Immune SA - ADR has given a return of -25.19% in the last 3 years.
AC Immune SA - ADR has a market capitalisation of $ 149 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of AC Immune SA - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the AC Immune SA - ADR and enter the required number of quantities and click on buy to purchase the shares of AC Immune SA - ADR.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Address: Building B, Lausanne, Switzerland, 1015
The CEO & director of Dr. Andrea Pfeifer Ph.D.. is AC Immune SA - ADR, and CFO & Sr. VP is Dr. Andrea Pfeifer Ph.D..
There is no promoter pledging in AC Immune SA - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| AC Immune SA - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-37.31
|
|
Operating margin(%)
|
-185.95
|
|
Net Margin(%)
|
-186.44
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of AC Immune SA - ADR was $0 Mln.
$0.07
(
